Nanobiotix ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $38.3MTTM through 31 Dec 2025
Net Income -$28.1MTTM through 31 Dec 2025
Free Cash Flow -$39.9MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 90.9% |
| EBITDA Margin | -24.1% |
| Operating Margin | -33.2% |
| Net Margin | -73.5% |
Returns
28.4%ROE
-35.4%ROA
Balance Sheet Health
Debt / Equity-1.13x
Current Ratio1.09x
Net Debt$42.6M
Cash & Equivalents$52.8M
Quality Metrics
Piotroski F-Score4 / 9
FCF Margin-104.3%
Rule of 40-87.4
Multi-Year Trend
RevenueFY2025: $32.6M
Diluted EPSFY2025: $0.00
Dividend
No dividend
Capital Allocation
Capex Intensity1.4%
Segment Performance
No segment data available.
Financials converted at 0.8513 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.